GlassScriptPhysician profile
Alan William Martin
NPI 1619943362
$14,837.24
in general payments reported to CMS, 2019-2025
66 companies · $1,873 in 2025
The $1,873 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,099 · 2020: $1,279 · 2021: $1,855 · 2022: $2,328 · 2023: $2,233 · 2024: $2,171 · 2025: $1,873.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,117 · Consulting Fee: $150 · Education: $10.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,116.58 |
| Consulting Fee | $150.00 |
| Education | $10.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,294.64 | 2021-2025 | |
| Alnylam Pharmaceuticals INC. | $1,043.52 | 2019-2025 | Onpattro |
| Biogen, INC. | $1,004.85 | 2019-2024 | Tysabri, Vumerity, Skyclarys |
| Genentech USA, INC. | $926.87 | 2019-2025 | Ocrevus, Enspryng, Ocrevus Zunovo |
| Argenx US, INC. | $706.79 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Alexion Pharmaceuticals, INC. | $692.76 | 2019-2024 | Ultomiris, Soliris |
| Ucb, INC. | $622.29 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Sunovion Pharmaceuticals INC. | $599.85 | 2019-2022 | |
| Lilly USA, LLC | $534.66 | 2019-2025 | Emgality, Kisunla, Amyvid |
| Pfizer INC. | $522.09 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $487.88 | 2019-2025 | |
| Avanir Pharmaceuticals, INC. | $433.30 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $411.05 | 2019-2025 | Nuplazid, Daybue |
| Genzyme Corporation | $407.40 | 2019-2025 | |
| Amgen INC. | $355.75 | 2019-2025 | Uplizna |
Show all 65 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,600,758.65 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.